Skip to main content

Advertisement

SpringerLink
Log in

Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study

  • Neurology and Preclinical Neurological Studies - Original Article
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system. Autoimmune inflammation is common in the early stages of MS. This stage is followed by the neurodegenerative process. The result of these changes is axon and myelin breakdown. Although MS is according to McDonald’s revised diagnostic criteria primarily a clinical diagnosis, paraclinical investigation methods are an important part in the diagnosis of MS. In common practice, magnetic resonance imaging of the brain and spinal cord, examination of cerebrospinal fluid (CSF) and examination of visual evoked potentials are used. There are an increasing number of studies dealing with biomarkers in CSF and their role in the diagnosis and treatment of MS. We hypothesized that the levels of some markers could be changed in MS in comparison with controls. We studied five inflammatory markers [interleukin-6 (IL-6), interleukin-8, interleukin-10 (IL-10), beta-2-microglobulin, orosomucoid]. CSF and serum levels of inflammatory markers were assessed in 38 patients with newly diagnosed MS meeting McDonald’s revised diagnostic criteria and in 28 subjects as a control group (CG). Levels of beta-2-microglobulin and interleukin-8 in CSF were found to be significantly higher in MS patients in comparison to CG (p < 0.001 resp. p = 0.007). No differences in other CSF markers (IL-6, IL-10 and orosomucoid) and serum levels of all markers between both groups were found. The levels of two studied inflammatory markers were found to be increased at the time of first clinical symptoms of MS. Research on the role of inflammatory and neurodegenerative markers in MS should continue.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Adam P, Sobek O, Táborský L, Hildebrand T, Tutterová O, Zácek P (2003) CSF and serum orosomucoid (alpha-1-acid glycoprotein) in patients with multiple sclerosis: a comparison among particular subgroups of MS patients. Clin Chim Acta 334(1–2):107–110

    Article  CAS  PubMed  Google Scholar 

  • Bagnato F, Durastanti V, Finamore L, Volante G, Millefiorini E (2003) Beta-2 microglobulin and neopterin as markers of disease activity i multiple sclerosis. Neurol Sci 24:S301–S304

    Article  PubMed  Google Scholar 

  • Bartosik-Psujek H, Stelmasiak Z (2005) The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol 12(1):49–54

    Article  CAS  PubMed  Google Scholar 

  • Bielekova B, Komori M, Xu Q, Reich DS, Wu T (2012) Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation. PLoS ONE 7(11):e48370

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Bjerrum OW, Bach FW, Zeeberg I (1988) Increased level of cerebrospinal fluid beta 2-microglobulin is related to neurologic impairment in multiple sclerosis. Acta Neurol Scand 78(1):72–75

    Article  CAS  PubMed  Google Scholar 

  • Carrieri PB, Indaco A, Maiorino A, Buscaino GA, Ponticiello A, Liberti A, Perrella O (1992) Cerebrospinal fluid beta-2-microglobulin in multiple sclerosis and AIDS dementia complex. Neurol Res 14(3):282–283

    CAS  PubMed  Google Scholar 

  • Franciotta D, Martino G, Zardini E, Furlan R, Bergamaschi R, Andreoni L, Cosi V (2001) Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 115(1–2):192–198

    Article  CAS  PubMed  Google Scholar 

  • Hirotani M, Niino M, Fukazawa T, Kikuchi S, Yabe I, Hamada S, Tajima Y, Sasaki H (2010) Decreased IL-10 production mediated by Toll-like receptor 9 in B cells in multiple sclerosis. J Neuroimmunol 221(1–2):95–100

    Article  CAS  PubMed  Google Scholar 

  • Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J (2005) Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128(Pt 5):988–1002

    Article  PubMed  Google Scholar 

  • Lund BT, Ashikian N, Ta HQ, Chakryan Y, Manoukian K, Groshen S, Gilmore W, Cheema GS, Stohl W, Burnett ME, Ko D, Kachuck NJ, Weiner LP (2004) Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol 155(1–2):161–171

    Article  CAS  PubMed  Google Scholar 

  • Maimone D, Gregory S, Arnason BG, Reder AT (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunol 32(1):67–74

    Article  CAS  PubMed  Google Scholar 

  • Martins TB, Rose JW, Jaskowski TD, Wilson AR, Husebye D, Seraj HS, Hill HR (2011) Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am J Clin Pathol 136(5):696–704

    Article  CAS  PubMed  Google Scholar 

  • Mirowska-Guzel DM, Kurowska K, Skierski J, Koronkiewicz M, Wicha W, Kruszewska J, Czlonkowski A, Czlonkowska A (2006) High dose of intravenously given glucocorticosteroids decrease IL-8 production by monocytes in multiple sclerosis patients treated during relapse. J Neuroimmunol 176(1–2):134–140 Epub 2006 May 24

    Article  CAS  PubMed  Google Scholar 

  • Modvig S, Degn M, Horwitz H, Cramer SP, Larsson HB, Wanscher B, Sellebjerg F, Frederiksen JL (2013) Relationship between cerebrospinal fluid biomarkers for inflammation, demyelination and neurodegeneration in acute optic neuritis. PLoS One 8(10):e77163. doi:10.1371/journal.pone.0077163

  • Neuteboom RF, Verbraak E, Voerman JS, van Meurs M, Steegers EA, de Groot CJ, Laman JD, Hintzen RQ (2009) First trimester interleukin 8 levels are associated with postpartum relapse in multiple sclerosis. Mult Scler 15(11):1356–1358

    Article  CAS  PubMed  Google Scholar 

  • Pul R, Moharregh-Khiabani D, Škuljec J, Skripuletz T, Garde N, Voss EV, Stangel M (2011) Glatiramer acetate modulates TNF-α and IL-10 secretion in microglia and promotes their phagocytic activity. J Neuroimmune Pharmacol 6(3):381–388

    Article  PubMed  Google Scholar 

  • Sladkova V, Mares J, Lubenova B, Zapletalova J, Stejskal D, Hlustik P, Kanovsky P (2011) Degenerative and inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients with relapsing–remitting course of disease and after clinical isolated syndrome. Neurol Res 33(4):415–420

    Article  CAS  PubMed  Google Scholar 

  • Stelmasiak Z, Kozioł-Montewka M, Dobosz B, Rejdak K, Bartosik-Psujek H, Mitosek-Szewczyk K, Belniak-Legieć E (2000) Interleukin-6 concentration in serum and cerebrospinal fluid in multiple sclerosis patients. Med Sci Monit 6(6):1104–1108

    CAS  PubMed  Google Scholar 

  • Vaknin-Dembinsky A, Balashov K, Weiner HL (2006) IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligosincreases dendritic cell IL-10 production. J Immunol 176(12):7768–7774

    Article  CAS  PubMed  Google Scholar 

  • Wen SR, Liu GJ, Feng RN, Gong FC, Zhong H, Duan SR, Bi S (2012) Increased levels of IL-23 and osteopontin in serum and cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 244(1–2):94–96

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Neurology, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

    Z. Matejčíková, J. Mareš, H. Přikrylová Vranová, J. Klosová, V. Sládková, J. Doláková & P. Kaňovský

  2. University Hospital Olomouc, Olomouc, Czech Republic

    Z. Matejčíková, J. Mareš, H. Přikrylová Vranová, J. Klosová, V. Sládková, J. Doláková & P. Kaňovský

  3. Department of Medical Biophysics, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

    J. Zapletalová

Authors
  1. Z. Matejčíková
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Mareš
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Přikrylová Vranová
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Klosová
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Sládková
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. Doláková
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Zapletalová
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. Kaňovský
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Z. Matejčíková.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Matejčíková, Z., Mareš, J., Přikrylová Vranová, H. et al. Cerebrospinal fluid inflammatory markers in patients with multiple sclerosis: a pilot study. J Neural Transm 122, 273–277 (2015). https://doi.org/10.1007/s00702-014-1244-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00702-014-1244-9

Keywords

Search

Navigation